South China Morning Post
Cross-border biotech deals grow more complex as US targets China investment links
Cross-border biotech deals between China and the United States are becoming more complicated and could face a modest slowdown as Washington steps up efforts to restrict investment and technology transfers, according to industry analysts…
View original source — South China Morning Post ↗
Related stories
Financial Times
HealthJun 19, 2026 · 1 min
AbbVie closes in on nearly $11bn deal for biotech Apogee Therapeutics
Financial Times
CNBC
HealthJun 9, 2026 · 1 min
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
CNBC
Financial Times
HealthJun 9, 2026 · 1 min
GSK in talks to buy cancer biotech Nuvalent for more than $9bn
Financial Times
CNA
WorldJun 17, 2026 · 1 min
Commentary: Beijing’s crackdown on overseas investing is making Hong Kong more important, not less
CNA